ADVERTISEMENT

Coronavirus vaccines: What we know about testing and availability

The World Health Organization says that there are more than 40 research effort to develop a coronavirus vaccine.

Employee Philipp Hoffmann, of German biopharmaceutical company CureVac, demonstrates research workflow on a vaccine for the coronavirus (COVID-19) disease at a laboratory in Tuebingen, Germany, March 12, 2020. Picture taken on March 12, 2020. REUTERS/Andreas Gebert
  • Two vaccine candidates are already undergoing human testing that could produce a coronavirus vaccine by as early as this fall.
  • Business Insider compiled a list of all the coronavirus vaccine candidates that are undergoing research or human trials.
  • Visit Business Insider's homepage for more stories .
ADVERTISEMENT

The drug industry and health officials are now racing to respond to the coronavirus outbreak as cases of COVID-19 mount, and the World Health Organization has declared it a pandemic.

There are more than 40 ongoing research efforts across the globe to develop a coronavirus vaccine, according to the World Health Organization .

Two vaccine candidates, for instance, have already started human testing in record timing. But it will still take at least a year to determine if any vaccine works against this virus.

ADVERTISEMENT

Here's is our list of the few vaccines that are undergoing human testing as well as other vaccine candidates that could become available in 2021.

Healthy volunteers are now being enrolled in Washington state and Georgia to test the first potential coronavirus vaccine developed by Moderna.

The upstart biotech developed the experimental vaccine in record time , going from sequencing the virus to dosing a patient in roughly two months and says it canhave a coronavirus vaccine ready for emergency use this fall .

ADVERTISEMENT

The company said on April 6 it has opened a trial for 40 healthy volunteers in Philadelphia and Kansas City, Missouri. Inovio expects early safety results by late summer and is aiming to produce 1 million doses by year's end.

ADVERTISEMENT

CanSino is famous for its help on producing an Ebola virus vaccine in 2017 . Now, it's working with the Beijing Institute of Biotechnology, and the research is funded by the Ministry of Science and Technology of China. That trial will enroll 108 participants in Wuhan, testing three dose strengths, according to a Chinese clinical trial registry .

ADVERTISEMENT

J&J identified a lead vaccine candidate in late March, planning to start human testing by September. The vaccine could gain emergency clearance for use as soon as early 2021, when tens of millions of doses would be available. The companyhopes to produce 1 billion doses by the end of 2021.

The $110 billion drugmaker, Sanofi, has the capacity for mass production. Its manufacturing plants in New York and Pennsylvania could make 100 million to 600 million doses per year.

ADVERTISEMENT

But the French pharma's timelines are slower than other approaches. The company has forecasted in early 2021 as a reasonable expectation to start human testing for both vaccine projects.

Pfizer is co-developing a COVID-19 vaccine with a German biotech called BioNTech. Pfizer and BioNTech expect to start a human trial of their vaccine by the end of April. The companies are working from their previous collaboration in 2018 to develop a flu shot.

ADVERTISEMENT

CureVac uses a messenger RNA platform that instructs cells how to make proteins. The unproven technology has shown it can speedily crank out potential vaccines, but has yet to bring a vaccine through approval.

ADVERTISEMENT

A research team out of the University of Queensland has been granted an additional $10 million from the Queensland state government in order to develop a coronavirus vaccine more quickly. The team said that a vaccine may be available by early 2021.

After receiving just under $1 million from the European Union to accelerate the development of a COVID-19 vaccine, ExpreS2ion Biotechnologies will be among dozens of companies conducting human testing by 2021.

ADVERTISEMENT

The British pharma giant GlaxoSmithKline is collaboration with Vir Biotechnology to test a potential medical treatment for patients already sick with COVID-19 within a few months, and then apply their understanding of the virus to vaccine development.

The partnership is aiming to start testing experimental antibody treatments in humans within the next three to five months.

ADVERTISEMENT

See Also:

FOLLOW BUSINESS INSIDER AFRICA

Unblock notifications in browser settings.
ADVERTISEMENT

Recommended articles

Egypt, Nigeria, and South Africa ranked as Africa's most polluted countries in new report

Egypt, Nigeria, and South Africa ranked as Africa's most polluted countries in new report

10 African countries with the lowest life expectancy according to the World Bank

10 African countries with the lowest life expectancy according to the World Bank

Kenyan women are more obese than their men - here’s why

Kenyan women are more obese than their men - here’s why

Africa’s richest man Dangote stands between Europe and $17 billion in revenue

Africa’s richest man Dangote stands between Europe and $17 billion in revenue

After months of exchanging blows, Kenya and Uganda takes steps towards resolution

After months of exchanging blows, Kenya and Uganda takes steps towards resolution

Africa's first black billionaire could join $2.9 billion Vivendi bid for MultiChoice

Africa's first black billionaire could join $2.9 billion Vivendi bid for MultiChoice

10 most dangerous African countries in 2024

10 most dangerous African countries in 2024

Russia’s nuclear influence expands further north of Africa

Russia’s nuclear influence expands further north of Africa

Navigating the future: How AI transforms selling on Amazon

Navigating the future: How AI transforms selling on Amazon

ADVERTISEMENT